Company update

Oslo, 21 April 2010 - Reference is made to the company update as per 6 April
2010. PCI Biotech has now been informed by University College Hospital (UCH) in
London that the hospital has in place the new personnel required to support the
ongoing Phase I/II study of Amphinex®. Hence, UCH is ready to include patients
on the fourth dose level from next week.



Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Bernt-Olav Røttingsnes, CFO, bor@pcibiotech.no, Mobile: +47 913 47 021






This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


[HUG#1406447]